how big is Vaidya Sane?

As of Jun 06, Vaidya Sane Ayurved Laboratories Ltd has a market capitalization of 160.00 Cr, classifying it as a Micro Cap company, with consolidated net sales of 19585.66 Cr and net profit of 1448.51 Cr over the latest four quarters.

Market Cap: <BR>As of Jun 06, Vaidya Sane Ayurved Laboratories Ltd has a market capitalization of 160.00 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: <BR>For the latest four quarters, the sum of Net Sales is 19585.66 Cr and the sum of Net Profit is 1448.51 Cr. This data is Consolidated.<BR><BR>Balance Sheet Snapshot: <BR>This is Consolidated data for the latest annual period ending in Mar'24. The Shareholder's Funds are reported at 55.60 Cr, and the Total Assets amount to 70.82 Cr.

What does Vaidya Sane do?

Vaidya Sane Ayurved Laboratories Ltd is a micro-cap company in the hospital industry, reporting net sales of ₹5,110 Cr and a net profit of ₹235 Cr for September 2023. Key metrics include a P/E ratio of 28.00 and a return on equity of 13.84%.

Overview:<BR>Vaidya Sane Ayurved Laboratories Ltd operates in the hospital industry and is categorized as a micro-cap company.<BR><BR>History:<BR>The company was originally incorporated in 1999 as a Private Limited Company and later converted into a Public Limited Company. The latest quarterly results reported net sales and profit for September 2023.<BR><BR>Financial Snapshot:<BR>Net Sales: 5,110 Cr (Quarterly Results - Sep 2023) <BR>Net Profit: 235 Cr (Quarterly Results - Sep 2023) <BR>Market-cap: Rs 160 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 28.00 <BR>Industry P/E: N/A <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.40 <BR>Return on Equity: 13.84% <BR>Price to Book: 3.86 <BR><BR>Contact Details:<BR>No Company Details Available <BR>Registrar Address: Not available.

When is the next results date for Vaidya Sane?

No Upcoming Board Meetings

Has Vaidya Sane declared dividend?

Yes, Vaidya Sane Ayurved Laboratories Ltd has declared a 2% dividend, amounting to ₹0.20 per share, with an ex-date of September 5, 2023. However, total returns over various periods have shown negative performance, with minimal contributions from dividends.

Yes, Vaidya Sane Ayurved Laboratories Ltd has declared a dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 2%<BR>- Amount per share: ₹0.20<BR>- Ex-date: 05 Sep 23<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -3.24%, the dividend return was 0%, resulting in a total return of -3.24%.<BR><BR>Over the past year, the price return was -1.3%, the dividend return was 0%, leading to a total return of -1.3%.<BR><BR>In the 2-year period, the price return was -41.09%, the dividend return was 0.08%, resulting in a total return of -41.01%.<BR><BR>For the 3-year period, the price return was -18.02%, the dividend return was 0.26%, which led to a total return of -17.76%.<BR><BR>In the 4-year period, the price return was 0%, the dividend return was 0%, resulting in a total return of 0.0%.<BR><BR>Over the last 5 years, both the price return and dividend return were 0%, leading to a total return of 0.0%.<BR><BR>Overall, while Vaidya Sane has declared a dividend, the total returns over various periods indicate a trend of negative performance, particularly in the longer term, with minimal contributions from dividends.

Who are the peers of the Vaidya Sane?

Vaidya Sane's peers include Max Healthcare, Apollo Hospitals, Fortis Health, and others. Management risk varies from excellent to below average, with Fortis Health showing the highest 1-year return at 59.65%, while Vaidya Sane, Sangani Hospital, and Aatmaj Health have a return of 0.00%.

Peers: The peers of Vaidya Sane are Max Healthcare, Apollo Hospitals, Fortis Health., Narayana Hrudaya, Global Health, Lotus Eye Hospit, Fortis Malar, Shanmuga Hos., Sangani Hospital, and Aatmaj Health.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare, Narayana Hrudaya, Global Health, Shanmuga Hos., and Aatmaj Health, while Good management risk is found at Apollo Hospitals and the rest. Average management risk is noted at Fortis Health., Lotus Eye Hospit, and Sangani Hospital, while Below Average management risk is seen at Fortis Malar. Growth is Excellent at Max Healthcare and Apollo Hospitals, Good at Fortis Health., Narayana Hrudaya, and Vaidya Sane, while Average growth is noted at Global Health, and Below Average growth is observed at Lotus Eye Hospit, Shanmuga Hos., Fortis Malar, Sangani Hospital, and Aatmaj Health. Capital Structure is Excellent at Max Healthcare and Shanmuga Hos., Good at Fortis Health., Narayana Hrudaya, Global Health, and Aatmaj Health, while Average is seen at Apollo Hospitals and Lotus Eye Hospit, and Below Average at Fortis Malar.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Fortis Health. at 59.65%, while the lowest is Sangani Hospital and Aatmaj Health, both at 0.00%. Vaidya Sane's 1-year return is also 0.00%, which is the same as Sangani Hospital and Aatmaj Health. Additionally, Global Health and Lotus Eye Hospit have negative six-month returns.

What is the technical trend for Vaidya Sane?

As of June 3, 2025, the market trend is mildly bullish, supported by a bullish weekly MACD and Bollinger Bands, although caution is advised due to mixed signals from the monthly MACD and daily moving averages.

As of 3 June 2025, the technical trend has changed from sideways to mildly bullish. The weekly MACD is bullish, supporting the positive outlook, while the monthly MACD is mildly bearish, indicating some caution. The Bollinger Bands on the weekly are bullish, reinforcing the upward momentum. However, the daily moving averages are mildly bearish, suggesting short-term weakness. The Dow Theory indicates a mildly bullish stance on both weekly and monthly time frames, and the On-Balance Volume (OBV) is also mildly bullish, reflecting positive accumulation. Overall, the current stance is mildly bullish, driven primarily by the weekly MACD and Bollinger Bands, despite some mixed signals from other indicators.

Who are in the management team of Vaidya Sane?

As of March 2022, the management team of Vaidya Sane includes Rohit Madhav Sane (Managing Director & CEO), Vidyut Bipin Ghag (Whole-time Director), and four Independent Directors: Ratnakar Venkappa Rai, Sushrut Raghavendra Dambal, Mahesh P. Kshirsagar, along with Abhishek Ajay Deshpande (Company Secretary & Compliance Officer).

As of March 2022, the management team of Vaidya Sane includes the following individuals:<BR><BR>1. Rohit Madhav Sane - Managing Director & CEO<BR>2. Vidyut Bipin Ghag - Whole-time Director<BR>3. Ratnakar Venkappa Rai - Independent Director<BR>4. Sushrut Raghavendra Dambal - Independent Director<BR>5. Mahesh P. Kshirsagar - Independent Director<BR>6. Abhishek Ajay Deshpande - Company Secretary & Compliance Officer<BR><BR>These members play key roles in the governance and operational management of the company.

Who are the top shareholders of the Vaidya Sane?

The top shareholders of Vaidya Sane are led by promoter Rohit Madhav Sane, who holds 66.29% of the shares, followed by public shareholder Virtuous Capital Limited with 4.17%. Individual investors own 21.94%, with no mutual funds or foreign institutional investors currently involved.

The top shareholders of Vaidya Sane include the promoters, with Rohit Madhav Sane holding the largest share at 66.29%. The highest public shareholder is Virtuous Capital Limited, which holds 4.17%. Additionally, individual investors collectively own 21.94% of the company. Notably, there are no mutual funds or foreign institutional investors currently holding shares in Vaidya Sane.

Should I buy, sell or hold Vaidya Sane?

How has been the historical performance of Vaidya Sane?

Vaidya Sane has shown significant growth from Mar'22 to Mar'25, with net sales rising to 89.85 Cr despite a decline from the previous year, and profit before tax increasing to 9.90 Cr. The company improved its operating profit and earnings per share, indicating a strong upward trend in revenue and profitability.

Answer:<BR>The historical performance of Vaidya Sane shows a significant growth trajectory, particularly from fiscal year Mar'22 to Mar'25.<BR><BR>Breakdown:<BR>Vaidya Sane's net sales increased from zero in Mar'22 to 89.85 Cr in Mar'25, although there was a decline from 99.33 Cr in Mar'24. Total operating income followed a similar trend, rising from zero to 89.85 Cr, with a slight decrease from the previous year. The company managed to reduce its total expenditure from 94.83 Cr in Mar'24 to 76.34 Cr in Mar'25, contributing to an operating profit (PBDIT) of 15.37 Cr in Mar'25, up from 6.25 Cr in Mar'24. Profit before tax also saw a notable increase, reaching 9.90 Cr in Mar'25 compared to 2.86 Cr in Mar'24, while profit after tax rose to 7.15 Cr from 1.99 Cr. The earnings per share (EPS) improved significantly from 1.88 in Mar'24 to 6.79 in Mar'25. On the balance sheet, total liabilities increased from 54.81 Cr in Mar'23 to 70.82 Cr in Mar'24, with total assets also rising to 70.82 Cr in Mar'24. Cash flow from financing activities showed a strong inflow of 14.00 Cr in Mar'24, contributing to a closing cash balance of 13.00 Cr, up from 1.00 Cr in the previous year. Overall, Vaidya Sane has demonstrated a robust growth pattern in revenue and profitability over the past few years.

Is Vaidya Sane overvalued or undervalued?

As of November 6, 2025, Vaidya Sane is considered very expensive and overvalued with a PE ratio of 48.20 and an EV to EBITDA of 26.00, significantly higher than its peers like Sun Pharma and Cipla, despite a strong year-to-date return of 90.47%.

As of 6 November 2025, the valuation grade for Vaidya Sane has moved from expensive to very expensive. The company is currently considered overvalued. Key ratios include a PE ratio of 48.20, an EV to EBITDA of 26.00, and a PEG ratio of 0.11, which indicates a significant premium compared to its peers.<BR><BR>In comparison to its industry peers, Sun Pharma has a PE ratio of 35.02 and an EV to EBITDA of 10.54, while Cipla is valued more attractively with a PE ratio of 22.27 and an EV to EBITDA of 5.53. Despite Vaidya Sane's strong year-to-date return of 90.47%, which outperforms the Sensex's 7.89%, the current valuation metrics suggest that the stock is not justified at its price level.

Which are the latest news on Vaidya Sane?

Why is Vaidya Sane falling/rising?

As of 04-Dec, the stock price of Vaidya Sane Ayurved Laboratories Ltd is stable at 275.00, with a year-to-date increase of 98.48%. Despite today's slight underperformance and decreased investor participation, the company shows strong long-term growth and financial stability.

As of 04-Dec, the stock price of Vaidya Sane Ayurved Laboratories Ltd is currently stable at 275.00, showing no change (0.00%). Despite this stability, the stock has demonstrated strong performance over the longer term, with a year-to-date increase of 98.48% and a one-year increase of 76.91%, significantly outperforming the benchmark Sensex, which has only risen by 10.10% and 6.40% respectively during the same periods.<BR><BR>However, today's performance indicates a slight underperformance relative to its sector, with a decline of 0.29%. Additionally, there has been a notable decrease in investor participation, as evidenced by a delivery volume of only 400 shares on December 3, which represents a drastic drop of 97.51% compared to the five-day average. This decline in trading activity may suggest a lack of investor interest at the current price level, which could contribute to the stock's inability to rise further today.<BR><BR>On a positive note, the company maintains a low debt-to-equity ratio, indicating financial stability, and has shown healthy long-term growth with an annual operating profit increase of 47.54%. These factors suggest that while the stock is not currently rising, it has a solid foundation for potential future growth. Overall, the combination of strong historical performance and current market conditions reflects a complex picture of stability rather than decline.